InsiderTrades

Form 4 for BIIB Biogen

Accepted 2024-09-05 00:00:00 ET · period of report 2024-08-30 · accession 0001127602-24-023505 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-09-05 2024-08-30 BIIB Singhal Priya Head of Development F - Tax $204.76 -807 5,747 -12% -$165.2K
D 2024-09-05 2024-08-30 BIIB Singhal Priya Head of Development M - OptEx $0.00 +1,668 6,554 +34% $0
D 2024-09-05 2024-09-03 BIIB Singhal Priya Head of Development S - Sale+OE $204.22 -431 5,316 -7% -$88.0K
D 2024-09-05 2024-08-30 BIIB Singhal Priya Head of Development M - OptEx $0.00 -1,668 1,669 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-08-30 F D 807 $204.76 5,747.48 D — —
2 Common Common Stock 2024-08-30 M A 1,668 $0.00 6,554.48 D — —
3 Common Common Stock 2024-09-03 S D 431 $204.22 5,316.48 D — —
4 Derivative Restricted Stock Unit 2024-08-30 M D 1,668 $0.00 1,669 D $0.00 · — to 2025-09-01 1,668 Common Stock (F1) This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date.